CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Executive or director change
- SC 13G Stake Amended Statement of Ownership
- 4 Grant or award Director acquired 816 shares (grant or award)
- 4 Grant or award Director acquired 612 shares (grant or award)
- 4 Grant or award Director acquired 919 shares (grant or award)
- 4 Grant or award Director acquired 1,337 shares (grant or award)
- 4 Grant or award Director acquired 1,337 shares (grant or award)
- 4 Open-market sale 10% owner sold 86 shares at $7.25 ($624)
- 4 Open-market sale 10% owner sold 307 shares at $7.25 ($2,226)
- 4 Open-market sale 10% owner sold 550 shares at $7.43 ($4,087)
- 4 Open-market sale 10% owner sold 2,300 shares at an average $7.42 ($17,074)
- 4 Open-market sale 10% owner sold 2,566 shares at an average $7.48 ($19,205)
- 4 Open-market sale 10% owner sold 458 shares at an average $7.84 ($3,591)
- 4 Open-market sale 10% owner sold 755 shares at an average $7.56 ($5,711)
- 4 Open-market sale 10% owner sold 6,093 shares at $7.52 ($45,790)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
Page 34 of 77 · 1,525 filings